| Outcome Measures: |
Primary: Change from baseline HbA1c at 1 month, In order to observe the change from baseline HbA1c at 1 month after GLP-1 RA treatment, 1 month after GLP-1 RA treatment|Change from baseline FPG at 1 month, In order to observe the change from baseline FPG at 1 month after GLP-1 RA treatment, 1 month after GLP-1 RA treatment|Change from baseline PPG at 1 month, In order to observe the change from baseline PPG at 1 month after GLP-1 RA treatment, 1 month after GLP-1 RA treatment|Change from baseline serum lipids at 1 month, In order to observe the change from baseline serum lipids at 1 month after GLP-1 RA treatment, 1 month after GLP-1 RA treatment|Change from baseline HbA1c at 3 month, In order to observe the change from baseline HbA1c at 3 month after GLP-1 RA treatment, 3 month after GLP-1 RA treatment|Change from baseline FPG at 3 month, In order to observe the change from baseline FPG at 3 month after GLP-1 RA treatment, 3 month after GLP-1 RA treatment|Change from baseline PPG at 3 month, In order to observe the change from baseline PPG at 3 month after GLP-1 RA treatment, 3 month after GLP-1 RA treatment|Change from baseline serum lipids at 3 month, In order to observe the change from baseline serum lipids at 3 month after GLP-1 RA treatment, 3 month after GLP-1 RA treatment|Change from baseline HbA1c at 6 month, In order to observe the change from baseline HbA1c at 6 month after GLP-1 RA treatment, 6 month after GLP-1 RA treatment|Change from baseline FPG at 6 month, In order to observe the change from baseline FPG at 6 month after GLP-1 RA treatment, 6 month after GLP-1 RA treatment|Change from baseline PPG at 6 month, In order to observe the change from baseline PPG at 6 month after GLP-1 RA treatment, 6 month after GLP-1 RA treatment|Change from baseline serum lipids at 6 month, In order to observe the change from baseline serum lipids at 6 month after GLP-1 RA treatment, 6 month after GLP-1 RA treatment | Secondary: incidence and severity of possible adverse reaction within 1 month after GLP-1 RA treatment, To evaluate the incidence and severity of possible adverse reaction within 1 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia, 1 month after GLP-1 RA treatment|incidence and severity of possible adverse reaction within 3 month after GLP-1 RA treatment, To evaluate the incidence and severity of possible adverse reaction within 3 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia, 3 month after GLP-1 RA treatment|incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment, To evaluate the incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia, 6 month after GLP-1 RA treatment
|
